Idioma:

An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients

Martínez-Estupiñán, Lina ; Hernández-Flórez, Diana ; Janta, Iustina ; Ovalles-Bonilla, Juan Gabriel ; Nieto, Juan Carlos ; González-Fernández, Carlos M ; Del Río, Tamara ; Monteagudo, Indalecio ; López-Longo, Francisco Javier ; Naredo, Esperanza ; Valor, Lara

Clinical and experimental rheumatology, 2018-01, Vol.36 (1), p.88-93 [Periódico revisado por pares]

Italy

Texto completo disponível

Citações Citado por

Enviar para

Título:
An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients
Autor: Martínez-Estupiñán, Lina ; Hernández-Flórez, Diana ; Janta, Iustina ; Ovalles-Bonilla, Juan Gabriel ; Nieto, Juan Carlos ; González-Fernández, Carlos M ; Del Río, Tamara ; Monteagudo, Indalecio ; López-Longo, Francisco Javier ; Naredo, Esperanza ; Valor, Lara
Assuntos: Adult ; Aged ; Anti-Citrullinated Protein Antibodies - blood ; Antirheumatic Agents - blood ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - immunology ; Biomarkers - blood ; Down-Regulation ; Drug Monitoring - methods ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Infliximab - blood ; Infliximab - therapeutic use ; Male ; Middle Aged ; Peptides, Cyclic - immunology ; Pilot Projects ; Rheumatoid Factor - blood ; Time Factors ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - immunology ; Young Adult
É parte de: Clinical and experimental rheumatology, 2018-01, Vol.36 (1), p.88-93
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: The aim of this study was to investigate the relationship between serum infliximab (IFX) levels and changes of RF and ACPA levels in patients with rheumatoid arthritis (RA). Enzyme-linked immunosorbent assays (ELISA) [Promonitor® IFX R1 (version 2) (Progenika Biopharma, Spain)] were used to measure drug levels and antidrug-antibodies (ADAb) in IFX RA-treated patients (n=19). Disease activity was assessed using DAS28. IgM rheumatoid factor (RF) and IgM, IgA and IgG anti-cyclic citrullinated peptide (ACPA) were determined through ELISA. A significant decrease in RF (p=0.01), ACPA IgG (p=0.007), IgM (p=0.01) and IgA (p=0.03) was observed in patients presenting adequate levels of serum IFX. No significant changes to RF or ACPA were observed in patients with undetectable IFX. Data from this study support the hypothesis that the anti-TNF antagonist IFX downregulates autoantibody levels in RA patients when IFX levels are detectable. Larger-scale studies need to be performed to establish RF and ACPA presence as therapeutic response predictive factors.
Editor: Italy
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients

Martínez-Estupiñán, Lina ; Hernández-Flórez, Diana ; Janta, Iustina ; Ovalles-Bonilla, Juan Gabriel ; Nieto, Juan Carlos ; González-Fernández, Carlos M ; Del Río, Tamara ; Monteagudo, Indalecio ; López-Longo, Francisco Javier ; Naredo, Esperanza ; Valor, Lara

Italy

Buscando em bases de dados remotas. Favor aguardar.